- Home
- IGMS vs MBI Comparison
IGMS vs MBI Comparison
Compare IGMS & MBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- MBI
- Stock Information
- Founded
- IGMS 1993
- MBI 1973
- Country
- IGMS United States
- MBI United States
- Employees
- IGMS N/A
- MBI N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- MBI Property-Casualty Insurers
- Sector
- IGMS Health Care
- MBI Finance
- Exchange
- IGMS Nasdaq
- MBI Nasdaq
- Market Cap
- IGMS 348.5M
- MBI 301.1M
- IPO Year
- IGMS 2019
- MBI 1987
- Fundamental
- Price
- IGMS $1.77
- MBI $6.05
- Analyst Decision
- IGMS Hold
- MBI Buy
- Analyst Count
- IGMS 8
- MBI 2
- Target Price
- IGMS $6.14
- MBI $6.75
- AVG Volume (30 Days)
- IGMS 779.9K
- MBI 416.6K
- Earning Date
- IGMS 03-06-2025
- MBI 02-26-2025
- Dividend Yield
- IGMS N/A
- MBI N/A
- EPS Growth
- IGMS N/A
- MBI N/A
- EPS
- IGMS N/A
- MBI N/A
- Revenue
- IGMS $2,918,000.00
- MBI N/A
- Revenue This Year
- IGMS $23.57
- MBI N/A
- Revenue Next Year
- IGMS $192.36
- MBI N/A
- P/E Ratio
- IGMS N/A
- MBI N/A
- Revenue Growth
- IGMS 57.64
- MBI N/A
- 52 Week Low
- IGMS $1.59
- MBI $3.22
- 52 Week High
- IGMS $22.50
- MBI $7.16
- Technical
- Relative Strength Index (RSI)
- IGMS 19.54
- MBI 46.25
- Support Level
- IGMS $1.59
- MBI $5.75
- Resistance Level
- IGMS $2.06
- MBI $6.47
- Average True Range (ATR)
- IGMS 0.45
- MBI 0.35
- MACD
- IGMS -0.30
- MBI -0.06
- Stochastic Oscillator
- IGMS 3.27
- MBI 22.73
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About MBI MBIA Inc.
MBIA Inc provides financial guaranty insurance for municipal bonds and asset-backed securities in the United States and internationally. It offers an unconditional guarantee to repay the principal and interest on these securities if the issuer defaults. MBIA insures bonds sold in the primary and secondary markets, as well as those held in unit investment trusts and by mutual funds. It operates in three segments: the United States public finance insurance, corporate, and international & structured finance insurance. U.S. public finance insurance portfolio is managed through National Public Finance Guarantee Corporation. International & structured finance insurance business is managed through MBIA Insurance Corporation and its subsidiary.